Livforsakringsbolaget Skandia Omsesidigt Buys New Stake in Phibro Animal Health Corporation $PAHC

Livforsakringsbolaget Skandia Omsesidigt acquired a new position in Phibro Animal Health Corporation (NASDAQ:PAHC) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 31,800 shares of the company’s stock, valued at approximately $1,759,000.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Phibro Animal Health by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 1,539,593 shares of the company’s stock worth $57,519,000 after buying an additional 13,884 shares during the period. State Street Corp raised its stake in Phibro Animal Health by 5.4% in the 4th quarter. State Street Corp now owns 942,279 shares of the company’s stock worth $35,204,000 after acquiring an additional 48,243 shares during the last quarter. Millennium Management LLC lifted its position in Phibro Animal Health by 4,227.1% during the 4th quarter. Millennium Management LLC now owns 641,313 shares of the company’s stock worth $23,959,000 after acquiring an additional 626,492 shares during the period. Geode Capital Management LLC lifted its position in Phibro Animal Health by 4.0% during the 4th quarter. Geode Capital Management LLC now owns 569,111 shares of the company’s stock worth $21,265,000 after acquiring an additional 21,951 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in Phibro Animal Health by 1.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 492,335 shares of the company’s stock valued at $18,394,000 after purchasing an additional 6,826 shares during the last quarter. 99.34% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Phibro Animal Health news, CEO Jack Bendheim sold 4,528 shares of the stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $48.49, for a total transaction of $219,562.72. Following the completion of the transaction, the chief executive officer owned 56,152 shares of the company’s stock, valued at $2,722,810.48. This represents a 7.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 39,728 shares of company stock worth $2,144,299. 50.13% of the stock is currently owned by insiders.

Phibro Animal Health Stock Up 0.1%

Shares of NASDAQ PAHC opened at $33.04 on Wednesday. The company’s 50-day simple moving average is $33.45 and its 200-day simple moving average is $43.51. Phibro Animal Health Corporation has a 52-week low of $25.58 and a 52-week high of $60.08. The firm has a market cap of $1.34 billion, a price-to-earnings ratio of 14.18, a price-to-earnings-growth ratio of 0.46 and a beta of 0.46. The company has a quick ratio of 1.26, a current ratio of 3.17 and a debt-to-equity ratio of 1.97.

Phibro Animal Health (NASDAQ:PAHC) last released its earnings results on Wednesday, May 6th. The company reported $0.76 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.04. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. The business had revenue of $383.54 million during the quarter, compared to analysts’ expectations of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. Equities analysts predict that Phibro Animal Health Corporation will post 3.08 EPS for the current fiscal year.

Phibro Animal Health Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, June 24th. Shareholders of record on Wednesday, June 3rd were paid a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a yield of 1.5%. The ex-dividend date was Wednesday, June 3rd. Phibro Animal Health’s payout ratio is 20.60%.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on PAHC shares. Wall Street Zen lowered Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Zacks Research downgraded Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 21st. Weiss Ratings lowered Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, June 15th. Finally, Citigroup cut their price target on shares of Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating on the stock in a report on Thursday, May 14th. One equities research analyst has rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Phibro Animal Health presently has an average rating of “Hold” and a consensus target price of $42.50.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.